On Apr. 8, 2020, Bellerophon Therapeutics announced submission of an Investigational New Drug (IND) application to the FDA to study the INOpulseﾮ inhaled nitric oxide system for the treatment of patients infected with COVID-19. INOpulse is the only therapy to deliver targeted nitric oxide by autonomously adjusting to the patientﾒs breathing pattern to ensure accurate and consistent drug delivery into the airways.